In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: Practical relevance of stage-specific differences

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3855-3859

  Vermeersch, Marieke ^a   Da Luz, Raquel Inocêncio ^a   Toté, Kim ^a   Timmermans, Jean Pierre ^a   Cos, Paul ^a   Maes, Louis ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTILEISHMANIAL AGENT; ANTIMONY; MILTEFOSINE; PX 6518; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; IC 50; IN VITRO STUDY; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMASTIGOTE;

AMPHOTERICIN B; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; LEISHMANIASIS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; PARASITIC SENSITIVITY TESTS; PHOSPHORYLCHOLINE; SAPONINS; TRITERPENES;

EID: 70349131162     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00548-09     Document Type: Article

References (40)

1. Alberio, S. O., S. S. Dias, F. P. Faria, R. A. Mortara, C. L. Barbieri, and E. F. Haapalainen. 2004. Ultrastructural and cytochemical identification of megasome in Leishmania (Leishmania) chagasi. Parasitol. Res. 92:246-254.
2. Ashutosh, S. Sundar, and N. Goyal. 2007. Molecular mechanisms of antimony resistance in Leishmania. J. Med. Microbiol. 56:143-153.
3. Berman, J. 2005. Clinical status of agents being developed for leishmaniasis. Expert Opin. Investig. Drugs 14:1337-1346.
4. Callahan, H. L., A. C. Portal, R. Devereaux, and M. Grogl. 1997. An axenic amastigote system for drug screening. Antimicrob. Agents Chemother. 41:818-822.
5. Chappuis, F., S. Sundar, A. Hailu, H. Ghalib, S. Rijal, R. W. Peeling, J. Alvar, and M. Boelaert. 2007. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5:873-882.
6. Croft, S. L. 2001. Monitoring drug resistance in leishmaniasis. Trop. Med. Int. Health 6:899-905.
7. Croft, S. L., S. Sundar, and A. H. Fairlamb. 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19:111-126.
8. Cunningham, I. 1977. New culture medium for maintenance of tsetse tissues and growth of trypanosomatids. J. Protozool. 24:325-329. (Pubitemid 8156212)
9. Debrabant, A., M. B. Joshi, P. F. P. Pimenta, and D. M. Dwyer. 2004. Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int. J. Parasitol. 34:205-217.
10. del Rayo Camacho, M., J. D. Phillipson, S. L. Croft, P. Rock, S. J. Marshall, and P. L. Schiff. 2002. In vitro activity of Triclisia patens and some bisbenzylisoquinoline alkaloids against Leishmania donovani and Trypanosoma brucei brucei. Phytother. Res. 16:432-436.
11. Drugs for Neglected Diseases Initiative. 2008. Annual report, 2007-2008. DNDi, Geneva, Switzerland.
12. Dube, A., N. Singh, S. Sundar, and N. Singh. 2005. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persists in in vitro and in vivo experimental models. Parasitol. Res. 96:216-223. (Pubitemid 40933669)
13. Ephros, M., A. Bitnun, P. Shaked, E. Waldman, and D. Zilberstein. 1999. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob. Agents Chemother. 43:278-282.
14. Escobar, P., S. Matu, C. Marques, and S. L. Croft. 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 81:151-157.
15. Fumarola, L., R. Spinelli, and O. Brandonisio. 2004. In vitro assays for evaluation of drug activity against Leishmania spp. Res. Microbiol. 155:224-230.
16. Gupta, N., N. Goyal, and A. K. Rastogi. 2001. In vitro cultivation and characterization of axenic amastigotes of Leishmania. Trends Parasitol. 17:150-153. (Pubitemid 32422185)
17. Holzer, T. R., W. R. McMaster, and J. D. Forney. 2006. Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana. Mol. Biochem. Parasitol. 146:198-218.
18. Kumar, D., A. Kulshrestha, R. Singh, and P. Salotra. 2009. In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob. Agents Chemother. 53:835-838.
19. Maes, L., D. Vanden Berghe, N. Germonprez, L. Quirijnen, P. Cos, N. De Kimpe, and L. Van Puyvelde. 2004. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral Leishmania species. Antimicrob. Agents Chemother. 48:130-136. (Pubitemid 38040188)
20. Mbongo, N., P. M. Loiseau, M. A. Billion, and M. Robert-Gero. 1998. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42:352-357.
21. Mikus, J., and D. Steverding. 2000. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol. Int. 48:265-269.
22. Mookerjee Basu, J., A. Mookerjee, P. Sen, S. Bhaumik, P. Sen, S. Banerjee, K. Naskar, S. K. Choudhuri, B. Saha, S. Raha, and S. Roy. 2006. Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob. Agents Chemother. 50:1788-1797.
23. Palatnik-de-Sousa, C. B. 2008. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26:1709-1724.
24. Pan, A. A., S. M. Duboise, S. Eperon, L. Rivas, V. Hodgkinson, Y. Traub- Cseko, and D. McMahon-Pratt. 1993. Developmental life cycle of Leishmania - cultivation and characterization of cultured extracellular amastigotes. J. Eukaryot. Microbiol. 40:213-223.
25. Pérez-Victoria, F. J., M. P. Sánchez-Cañete, K. Seifert, S. L. Croft, S. Sundar, S. Castanys, and F. Gamarro. 2006. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist. Updat. 9:26-39.
26. Rakotomanga, M., S. Blanc, K. Gaudin, P. Chaminade, and P. M. Loiseau. 2007. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 51:1425-1430.
27. Rijal, S., F. Chappuis, R. Singh, P. A. Bovier, P. Acharya, B. M. Karki, M. L. Das, P. Desjeux, L. Loutan, and S. Koirala. 2003. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans. R. Soc. Trop. Med. Hyg. 97:350-354.
28. Roberts, W. L., J. D. Berman, and P. M. Rainey. 1995. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob. Agents Chemother. 39:1234-1239.
29. Seifert, K., P. Escobar, and S. Croft. 2009. Activity of current anti-leishmanial drugs in in vitro macrophage-amastigote model is dependent on the host macrophage, poster 398. Fourth World Cong. Leishmaniasis, Lucknow, India, 3 to 7 February 2009.
30. Seifert, K., F. J. Pérez-Victoria, M. Stettler, M. P. Sánchez-Cañete, S. Castanys, F. Gamarro, and S. L. Croft. 2007. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int. J. Antimicrob. Agents 30:229-235.
31. Sereno, D., and J.-L. Lemesre. 1997. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob. Agents Chemother. 41:972-976.
32. Sereno, D., M. Cavaleyra, K. Zemzoumi, S. Maquaire, A. Ouaissi, and J. L. Lemesre. 1998. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob. Agents Chemother. 42:3097-3102.
33. V reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 276:3971-3976.
34. Shimony, O., and C. L. Jaffe. 2008. Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J. Microbiol. Methods 75:196-200.
35. Smith, A. C., V. Yardley, J. Rhodes, and S. L. Croft. 2000. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 44:1494-1498.
36. Sundar, S., and H. W. Murray. 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull. W. H. O. 83:394-395.
37. Tavares, J., A. Ouaissi, P. K. Lin, A. Tomás, and A. Cordeiro-da-Silva. 2005. Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes. Int. J. Parasitol. 35:637-646.
38. Teixeira, M. C., R. de Jesus Santos, R. B. Sampaio, L. Pontes-de-Carvalho, and W. L. Dos-Santos. 2002. A simple and reproducible method to obtain large numbers of axenic amastigotes of different Leishmania species. Parasitol. Res. 88:963-968.
39. Ueda-Nakamura, T., M. Attias, and W. de Souza. 2007. Comparative analysis of megasomes in members of the Leishmania mexicana complex. Res. Microbiol. 158:456-462.
40. Urbina, J. A. 2006. Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites. Trans. R. Soc. Trop. Med. Hyg. 100:S9-S16.